Partners & News

Featured Updates

  • NaDeNo joins AstraZeneca BioVentureHub

    April 3, 2025

    NaDeNo joins AstraZeneca BioVentureHub

    We are proud to announce that NaDeNo Nanoscience AS has been selected to join the AstraZeneca BioVentureHub, located at AstraZeneca’s R&D center in Gothenburg, Sweden. The BioVentureHub is an invitation-only ecosystem designed to foster close collaboration between emerging life science companies and AstraZeneca’s scientific and development teams. As the second Norwegian company to join, NaDeNo’s [...]

  • NaDeNo Welcomes Dr. Jens Bjørheim as Chief Medical Officer

    April 2, 2025

    NaDeNo Welcomes Dr. Jens Bjørheim as Chief Medical Officer

    We’re excited to welcome Jens Bjørheim to the NaDeNo team as our Chief Medical Officer. Jens brings a wealth of experience in clinical development and biotech leadership, and he will play a pivotal role in advancing our lead candidate from preclinical promise to patient impact. As CMO, he will lead our clinical strategy and trial [...]

NaDeNo Collaborates With Leading Organizations

A selection of partners across the healthcare and research ecosystem

Innovation & Testing

Organizations that contribute to preclinical research, early testing, and technology development.

Clinical Development

Renowned clinical institutions driving patient-focused trials to validate efficacy and safety in real-world settings.

Manufacturing & Supply Chain

Partners enabling production, scalability, and raw material sourcing.

Funding & Ecosystems

Organizations providing financial support, innovation clusters, and strategic networks.

Latest Updates

  • NaDeNo joins AstraZeneca BioVentureHub

    April 3, 2025

    NaDeNo joins AstraZeneca BioVentureHub

    We are proud to announce that NaDeNo Nanoscience AS has been selected to join the AstraZeneca BioVentureHub, located at AstraZeneca’s R&D center in Gothenburg, Sweden. The BioVentureHub is an invitation-only ecosystem designed to foster close collaboration between emerging life science companies and AstraZeneca’s scientific and development teams. As the second Norwegian company to join, NaDeNo’s [...]

  • NaDeNo Welcomes Dr. Jens Bjørheim as Chief Medical Officer

    April 2, 2025

    NaDeNo Welcomes Dr. Jens Bjørheim as Chief Medical Officer

    We’re excited to welcome Jens Bjørheim to the NaDeNo team as our Chief Medical Officer. Jens brings a wealth of experience in clinical development and biotech leadership, and he will play a pivotal role in advancing our lead candidate from preclinical promise to patient impact. As CMO, he will lead our clinical strategy and trial [...]

  • NaDeNo Tops PHOENIX OITB Rankings: A Big Leap Toward Clinical Trials

    February 28, 2025

    NaDeNo Tops PHOENIX OITB Rankings: A Big Leap Toward Clinical Trials

    We’re thrilled to share that out of many exceptional applications, NaDeNo achieved the highest evaluation scores from the prestigious PHOENIX OITB Open Call initiative! This recognition underscores the strength of our proprietary nanoparticle technology and the impact it promises for cancer therapy Thanks to this achievement, we now gain access to PHOENIX OITB comprehensive [...]

  • NaDeNo welcomes Gudrun Trøite as Head of Operations

    August 28, 2024

    NaDeNo welcomes Gudrun Trøite as Head of Operations

    We are thrilled to welcome Gudrun Trøite to the NaDeNo team as Head of Operations. Gudrun has 20 years’ drug development experience from the Norwegian biotech industry, including Ultimovacs ASA and Photocure, where she has held various leading roles within clinical operations, regulatory and quality assurance. She has successfully led multi-national studies within various indications [...]

  • Intraperitoneal administration of cabazitaxel-loaded nanoparticles in peritoneal metastasis models

    February 27, 2023

    Intraperitoneal administration of cabazitaxel-loaded nanoparticles in peritoneal metastasis models

    Read the full publication here What you’ll learn in this article: PACA drug encapsulation improves treatment response in peritoneal metastases models. Intraperitoneal injection of PACA nanoparticles provides a beneficial drug biodistribution. Drug encapsulation in PACA nanoparticles improves intraperitoneal drug retention. The taxane cabazitaxel is a promising chemotherapy option for peritoneal metastases. Abstract: Colorectal and ovarian [...]

  • NaDeNo Feaured in Norwegian SciTechNews

    January 31, 2023

    NaDeNo Feaured in Norwegian SciTechNews

    What you’ll learn in this article: This article from Norwegian SciTech News will provide deeper understanding of NaDeNo’s innovative nanoparticle-based drug delivery system. Read the full article Peritoneal cancer is difficult to treat and has a poor survival prognosis. But a new and effective nanomedicine delivery system is offering some hope. The company is called [...]